31 May 2009
We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical
biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD). ...
31 May 2009
The overall goal of the study is to evaluate how research participants in Parkinson Disease
studies that include brain imaging with a dopamine transporter ligand choose to receive the ...
25 Mar 2009
Measurement of mGluR5 binding capacity in the brain, may be a valuable tool in the early
detection, understanding, or evaluation of Parkinson and Huntington diseases. The goal of
this ...
15 Jan 2008
To assess the dynamic uptake and washout of 123-I CLINDE, a potential imaging biomarker for inflammatory changes in brain, using single photon emission computed tomography (SPECT) in similarly aged ...
07 Nov 2007
The main objectives of this protocol are as follows:
1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in
patients with Parkinson disease (PD) ...
24 Jan 2007
The overall plan of this project is to evaluate [123I] mZINT as a tool to assess SERT density in humans. This protocol will be completed in three parts. In Part A serial dynamic SPECT will be ...
21 Nov 2006
The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT ...
09 Oct 2006
This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT ...
